The panel's decision was based almost entirely on the Jupiter trial, a study funded by Crestors maker, AstraZeneca, that compared a daily dose
of Crestor to
placebo in nearly 18,000 people who fit the
description used by the panel (and who would not be eligible for a statin under the current guidelines).